A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-12 and is reviewed periodically as new material appears.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
=== T cell epitopes === T cell epitopes are presented on the surface of an antigen-presenting cell, where they are bound to major histocompatibility complex (MHC) molecules. In humans, professional antigen-presenting cells are specialized to present MHC class II peptides, whereas most nucleated somatic cells present MHC class I peptides. T cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, 13–17 amino acids in length, and non-classical MHC molecules also present non-peptidic epitopes such as glycolipids.
=== Thermoresponsivity in organic solvents === Due to the low entropy of mixing, miscibility gaps are often observed for polymer solutions. Many polymers are known that show UCST or LCST behavior in organic solvents. Examples for organic polymer solutions with UCST are polystyrene in cyclohexane, polyethylene in diphenylether or polymethylmethacrylate in acetonitrile. An LCST is observed for, e.g., polypropylene in n-hexane, polystyrene in butylacetate or polymethylmethacrylate in 2-propanone.
=== Deep sea alkaline vents === Nick Lane believes that no known life forms could have utilized zinc-sulfide based photosynthesis, lightning, volcanic pyrite synthesis, or UV radiation as a source of energy. Rather, he instead suggests that deep sea alkaline vents is more likely to have been a source energy for early cellular life. Serpentinization at alkaline hydrothermal vents produce methane and ammonia. Mineral particles that have similar properties to enzymes at deep sea vents would catalyze organic compounds out of dissolved CO2 within seawater. Porous rock might have promoted condensation reactions of biopolymers and act as a compartment of membranous structures, however it is unknown about how it could promote coding and metabolism. Acetyl phosphate, which is readily synthesized from thioacetate, can promote aggregation of adenosine monophosphate of up to 7 monomers which is considered energetically favored in water due to interactions between nucleobases. Acetyl phosphate can stabilize aggregation of nucleotides in the presence of Na+ and could possibly promote polymerization at mineral surfaces or lower water activity. An external proton gradient within a membrane would have been maintained between the acidic ocean and alkaline seawater. The descendants of the last universal common ancestor, bacteria and archaea, were probably methanogens and acetogens. The earliest microfossils, dated to be 4.28 to 3.77 Ga, were found at hydrothermal vent precipitates. These microfossils suggest that early cellular life began at deep sea hydrothermal vents.
Eugenic philosophy claimed scientific legitimacy to uphold racial stereotypes of latino/as, deeming them as unfit and even "hyper-fertile, inadequate mothers, criminally inclined, and more prone to feeblemindedness." At a time of segregation and growing anti-Mexican immigration sentiment, eugenic programs have been linked to efforts to reduce immigration. The laws in California from 1909 to 1979 allowed for nonconsensual sterilization of over 20,000 individuals. The forced sterilizations in California began in 1909 when a eugenics law was passed. It allowed doctors to sterilize people who were thought to be "unfit" to have children at state hospitals. Before this law was nullified in 1979, more than 20,000 people, including teenagers were victims of this sterilization. Doctors recommended people who they thought should be sterilized for certain reasons; this included not only people with a medical condition but also perfectly healthy ones as well. Minors as young as thirteen years old were sterilized. This law was meant to keep the "undesirable population" from growing. Women of Latina Origin were 59% more likely to be sterilized than women who were not of latino descent. An example of California's eugenic and neo-eugenic practices is a case from 1966. Nancy Hernandez was a 21-year-old mother of two in Santa Barbara, California. Nancy pleaded guilty, in 1966, for being with her boyfriend, Joseph Sanchez, while he used illegal narcotics.
=== Metabolism === Ibutilide has a high systemic plasma clearance that closes to the hepatic blood flow (29mL/min/kg). Its metabolic pathway is via liver's cytochrome P450 system by isoenzymes other than CYP3A4 and CYP2D6 by which the heptyl side chain of ibutilide is oxidized. With eight metabolites are detected in the urine, however, only one is an active metabolite that shares the similar electrophysiologic property of the Class III antiarrhythmic agents. The plasma concentration of this metabolite is only less than 10% of ibutilide.
Sources: en.wikipedia.org
Poor milk intake can be caused by poor milk transfer by the infant or by true low milk supply by the mother. When the milk "comes in" appropriately, but is followed by decreased milk supply, this is most often caused by allowing milk to remain in the breasts for long periods of time, or insufficiently draining the breasts during feeds. If the baby is latching and swallowing well (signs of good milk transfer), but is not gaining weight as expected or is showing signs of dehydration, low milk supply in the mother can be suspected, and a lactation specialist should be consulted.
Pain in the involved body part Temporarily decreased organ function Later symptoms are closely related to infarction of the affected tissue. This may cause permanently decreased organ function. For example, symptoms of myocardial infarction mainly include chest pain, dyspnea, diaphoresis (an excessive form of sweating), weakness, light-headedness, nausea, vomiting, and palpitations. Symptoms of limb infarction include coldness, decreased or no pulse beyond the site of blockage, pain, muscle spasm, numbness and tingling, pallor and muscle weakness, possibly to the grade of paralysis in the affected limb.
Caution should be exercised when collecting specimens from potentially polluted or contaminated sites, as several studies have shown that the fruit bodies can bioaccumulate toxic heavy metals like mercury, cadmium, caesium and polonium. Bioaccumulated metals or radioactive fission decay products are like chemical signatures: chemical and radiochemical analysis can be used to identify the origin of imported specimens, and for long-term radioecological monitoring of polluted areas. Porcini are sold fresh in markets in summer and autumn in Europe and Russia, and dried or canned at other times of the year, and distributed worldwide to countries where they are not otherwise found. They are eaten and enjoyed raw, sautéed with butter, ground into pasta, in soups, and in many other dishes. In France, they are used in recipes such as cèpes à la Bordelaise, cèpe frits and cèpe aux tomates. Porcini risotto is a traditional Italian autumn dish. Porcini are a feature of many cuisines, including Provençal, and Viennese. In Thailand they are used in soups and consumed blanched in salads. Porcini can also be frozen, either while raw or after cooking in butter. The colour, aroma, and taste of porcini deteriorate noticeably after being frozen for four months. Blanching (or soaking and blanching) as a processing step before freezing can extend the freezer life to 12 months. They are also one of the few species sold commercially as pickled mushrooms.
=== From ore === α-spodumene is roasted at 1100 °C for 1h to make β-spodumene, then roasted at 250 °C for 10 minutes with sulfuric acid. As of 2020, Australia was the world's largest producer of lithium intermediates, all based on spodumene. In recent years mining companies have begun exploration of lithium projects throughout North America, South America and Australia to identify economic deposits that can potentially bring new supplies of lithium carbonate online to meet the growing demand for the product.
== Target == GsMTx-4 mainly targets mechanosensitive channels from the Piezo and TRP families, such as Piezo1 and TRPC6 which are generally bilayer tension-sensitive. This corresponds to the strong bilayer partitioning energy of GsMTx-4. It also targets a spectrum of voltage-dependent sodium channels (human Nav1.1- Nav1.7), human ERG channels (Kv11.1 and Kv11.2), and acetylcholine receptors.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.